Form 4: Generation Bio Acquired by XOMA Royalty Corp.

Generation Bio Co. has been acquired by XOMA Royalty Corporation, with shareholders receiving cash and contingent value rights.

Summary

• Generation Bio Co. (GBIO) was acquired by XOMA Royalty Corporation (Parent) and its wholly-owned subsidiary XRA 7 Corp. (Merger Sub).
• The Agreement and Plan of Merger was dated December 15, 2025, and the merger became effective on February 9, 2026.
• Shareholders received a purchase price of $4.2913 per share in cash, without interest and less any applicable tax withholding.
• Shareholders also received one non-tradeable Contingent Value Right (CVR) per share, with an estimated maximum contingent consideration amount of $25.01 per CVR.
• Following the merger, Generation Bio Co. continues as the surviving corporation and a wholly-owned subsidiary of XOMA Royalty Corporation.
• Director Jason P. Rhodes's direct and indirect common stock holdings were converted according to the merger terms, resulting in zero beneficial ownership of common stock following the transaction.
• In-the-money stock options (exercise price less than $4.2913) held by the reporting person were fully vested, cancelled, and converted into a cash payment.
• Out-of-the-money stock options (exercise price equal to or greater than $4.2913) held by the reporting person were automatically cancelled for no consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event for former shareholders, as they received an immediate cash payment and retain potential upside through the CVRs, though the CVR value is contingent.

Positives

• Former shareholders received an immediate cash payment of $4.2913 per share.
• Former shareholders also received a Contingent Value Right (CVR) with an estimated maximum contingent consideration of $25.01 per CVR, offering potential future upside.
• In-the-money stock options were cashed out, providing value to option holders.

Negatives

• Out-of-the-money stock options were cancelled for no consideration, resulting in a loss of potential value for those option holders.
• Generation Bio Co. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of XOMA Royalty Corporation.

Risks

• The value of the Contingent Value Rights (CVRs) is contingent upon future events and is not guaranteed, with an 'estimated maximum' rather than a guaranteed payment.
• Former shareholders no longer participate in the future growth or decline of Generation Bio Co. as an independent entity.

Future Outlook

Generation Bio Co. will operate as a wholly-owned subsidiary of XOMA Royalty Corporation, with its former public shareholders now holding cash and contingent value rights.

Management Comments

• The filing is a Form 4, which reports insider transactions, not management commentary on strategy or performance. It includes legal disclaimers of beneficial ownership by the reporting person for certain indirect holdings.

Industry Context

StockSavvy.ai notes that this acquisition reflects ongoing consolidation within the biotechnology sector, where larger entities often acquire smaller, innovative companies to expand their pipelines or technology platforms. The use of CVRs is a common mechanism in biotech mergers to bridge valuation gaps and share future development risks/rewards.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of this acquisition, combining an upfront cash payment with a Contingent Value Right (CVR), is a common strategy in the biotechnology and pharmaceutical industries.
• Similar CVR structures have been used in acquisitions like Sanofi's acquisition of Principia Biopharma or Bristol Myers Squibb's acquisition of Celgene, where future payments are tied to regulatory milestones or sales targets.
• The specific values ($4.2913 cash, up to $25.01 CVR) would need to be compared against recent biotech M&A deals for companies with similar development stages and therapeutic areas to assess their competitiveness, but the mechanism itself aligns with industry practice.

Stakeholder Impact

• Shareholders: Received cash and CVRs, no longer hold equity in an independent public company.
• Employees: Generation Bio Co. continues as a subsidiary, implying continued employment, though potential integration changes are not detailed.
• Creditors: The merger structure typically involves assumption of liabilities by the acquiring entity, but specific details are not in this Form 4.

Next Steps

• Former Generation Bio Co. shareholders will await potential future payments from the Contingent Value Rights (CVRs).
• Generation Bio Co. will continue operations as a wholly-owned subsidiary of XOMA Royalty Corporation.

Key Dates

Keywords

Generation Bio Co., GBIO, XOMA Royalty Corporation, Merger, Acquisition, Contingent Value Right, CVR, Tender Offer, SEC Form 4, Biotechnology, Pharmaceutical